News
STAA
25.89
+4.40%
1.09
Swiss stocks - Factors to watch on December 18
Reuters · 3h ago
DEFENDER CAPITAL REITERATES INTENTION TO VOTE AGAINST STAAR SURGICAL'S PROPOSED SALE TO ALCON INC.
Reuters · 11h ago
Broadwood urges Staar Surgical shareholders to vote against Alcon transaction
TipRanks · 15h ago
STAAR Surgical Shareholders Poised to Reject Sale to Alcon
Reuters · 15h ago
Press Release: Broadwood Partners Issues Open -2-
Dow Jones · 15h ago
Press Release: Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
Dow Jones · 15h ago
Staar Surgical urges stockholders to vote for Alcon transaction
TipRanks · 17h ago
Broadwood Challenges Alcon Deal as STAAR Surgical Shareholder Vote Looms
Reuters · 17h ago
STAAR Surgical Stockholders to Vote on Alcon's $30.75 Per Share Cash Offer
Reuters · 17h ago
Press Release: STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
Dow Jones · 17h ago
Press Release: STAAR Stockholders Have a Choice: -2-
Dow Jones · 17h ago
Yunqi Capital says remains opposed to STAAR’s proposed merger with Alcon
TipRanks · 1d ago
Press Release: Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory
Dow Jones · 1d ago
Press Release: Yunqi Capital Comments on Proxy -2-
Dow Jones · 1d ago
*Staar Surgical: Increased Alcon Merger Price of $30.75 Per Shr Is Attractive Outcome for STAAR Stockholders >STAA
Dow Jones · 1d ago
*Staar Surgical: Independent Industry Analysts See Value to Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction >STAA
Dow Jones · 1d ago
STAAR Surgical Amends Alcon Merger Agreement to Offer $30.75 Per Share
Reuters · 1d ago
Press Release: Independent Industry Analysts -2-
Dow Jones · 1d ago
Press Release: Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
Dow Jones · 1d ago
Broadwood Partners Slams Alcon–STAAR Deal, Flag Sale Process Concerns
Benzinga · 1d ago
More
Webull provides a variety of real-time STAA stock news. You can receive the latest news about Staar Surg through multiple platforms. This information may help you make smarter investment decisions.
About STAA
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.